NewsBenzingaインテルの押し目買いは間違いかもしれない、アナリストが警告――「悪い計画」と生産能力の問題が解決するまで「死に金」状態 インテルの押し目買いは間違いかもしれない、アナリストが警告――「悪い計画」と生産能力の問題が解決するまで「死に金」状態 Benzinga 2026.11.02 09:47 (GMT+0) Open on Benzinga Other news TAT Techs Q3 EPS $0.58 Beats $0.40 Estimate, Sales $55.563M Beat $52.752M Estimate Baird Maintains Outperform on Carrier Global, Lowers Price Target to $70 Karyopharm Therapeutics Enters Restructuring Agreement With Lenders, Clearing Path For A Merger With Ayrmid; Secures Commitments For Up To $55M Of Debtor-In-Possession Financing Equinor CEO Says Shipping Costs Have Rapidly Changed, Efficient Market That We Were Used To Is Not There Anymore Kazia Therapeutics Says Two Abstracts Highlighting Paxalisib Tumor And Immune Reprogramming Research Accepted For Poster Presentation At 2026 San Antonio Breast Cancer Symposium DA Davidson Upgrades Franklin Electric to Buy, Raises Price Target to $135
Karyopharm Therapeutics Enters Restructuring Agreement With Lenders, Clearing Path For A Merger With Ayrmid; Secures Commitments For Up To $55M Of Debtor-In-Possession Financing
Equinor CEO Says Shipping Costs Have Rapidly Changed, Efficient Market That We Were Used To Is Not There Anymore
Kazia Therapeutics Says Two Abstracts Highlighting Paxalisib Tumor And Immune Reprogramming Research Accepted For Poster Presentation At 2026 San Antonio Breast Cancer Symposium